A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02801578 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Ibrutinib

Sponsor

M.D. Anderson Cancer Center